



## Early View

Original article

### **Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact**

Martina Bonifazi, Nicola Sverzellati, Eva Negri, Joseph Jacob, Ryoko Egashira, Joanna Moser, Sara Piciocchi, Federico Mei, Angelo De Lauretis, Dina Visca, Nicole Goh, Matteo Bonini, Laura Cirilli, Carlo La Vecchia, Felix Chua, Vasileios Kouranos, George Margaritopoulos, Maria Kokosi, Toby M. Maher, Stefano Gasparini, Armando Gabrielli, Athol U. Wells, Elisabetta A. Renzoni

Please cite this article as: Bonifazi M, Sverzellati N, Negri E, *et al.* Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. *Eur Respir J* 2020; in press (<https://doi.org/10.1183/13993003.02135-2019>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

## **Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact**

Martina Bonifazi<sup>1,2,3</sup>, Nicola Sverzellati<sup>4</sup>, Eva Negri<sup>5</sup>, Joseph Jacob<sup>6,7</sup>, Ryoko Egashira<sup>8</sup>, Joanna Moser<sup>9</sup>, Sara Piciocchi<sup>10</sup>, Federico Mei<sup>2</sup>, Angelo De Lauretis<sup>3,11</sup>, Dina Visca<sup>3,12</sup>, Nicole Goh<sup>13,14</sup>, Matteo Bonini<sup>15,16</sup>, Laura Cirilli<sup>1</sup>, Carlo LaVecchia<sup>17</sup>, Felix Chua<sup>3</sup>, Vasileios Kouranos<sup>3</sup>, George Margaritopoulos<sup>3,18</sup>, Maria Kokosi<sup>3</sup>, Toby M Maher<sup>3</sup>, Stefano Gasparini<sup>1,2</sup>, Armando Gabrielli<sup>19</sup>, Athol U Wells<sup>3</sup>, and Elisabetta A Renzoni<sup>3</sup>

<sup>1</sup>Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy;

<sup>2</sup>Pulmonary Disease Unit, Department of Internal Medicine, Azienda Ospedali Riuniti, Ancona, Italy

<sup>3</sup>Interstitial Lung Disease Unit, Royal Brompton Hospital, Imperial College, London, UK

<sup>4</sup>Radiology, Department of Medicine and Surgery, Università di Parma

<sup>5</sup> Department of Biomedical and Clinical Sciences “Luigi Sacco”, Università degli Studi di Milano, Milano, Italy

<sup>6</sup> Department of Respiratory Medicine, University College London, London, UK

<sup>7</sup> Centre for Medical Image Computing, University College London, London, UK

<sup>8</sup> Department of Radiology, Faculty of Medicine, Saga University, Saga city, Japan

<sup>9</sup> Department of Radiology, St George's University Hospitals NHS Foundation Trust, London, UK

<sup>10</sup> Radiology Unit, Ospedale GB Morgagni, Forlì, Italy

<sup>11</sup> Pulmonary Diseases Unit, Azienda Ospedaliera “Guido Salvini”, Garbagnate Milanese, Italy

<sup>12</sup> Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy

<sup>13</sup> Department of Respiratory Medicine, Austin Hospital, Melbourne, VIC, Australia

<sup>14</sup> Institute for Breathing and Sleep, Melbourne, VIC, Australia.

<sup>15</sup> National Heart and Lung Institute (NHLI), Imperial College London and Royal Brompton Hospital, London

<sup>16</sup> Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A.Gemelli- IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

<sup>17</sup> Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

<sup>18</sup> Interstitial Lung Disease Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Manchester, UK

<sup>19</sup> Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy

**Correspondence to:**

Prof. Martina Bonifazi

Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche,

Via Tronto 10/a, Ancona, Italy

bonifazimarti@gmail.com

**Keywords:** systemic sclerosis, interstitial lung disease, pleuroparenchymal fibroelastosis, survival

**Take-home message**

We provide a thorough assessment of pleuroparenchymal fibroelastosis (PPFE) prevalence, severity and clinical impact in two large cohorts of scleroderma patients (Total N=359). PPFE was present in 18% of patients and independently predicted mortality.

## **Abstract**

Interstitial lung disease (ILD) in systemic sclerosis (SSc) is a major cause of morbidity and mortality, mostly presenting as nonspecific interstitial pneumonia. Little is known about the prevalence of pleuroparenchymal fibroelastosis (PPFE), a specific entity affecting the visceral pleura and subpleural parenchyma. We set out to estimate PPFE prevalence in two large cohorts of SSc patients and to assess its impact on survival and functional decline.

A total of 359 SSc patients, derived from two referral centers in two different countries (UK and Italy), were included. The first available high-resolution computed tomography scan was independently evaluated by two radiologists blind to clinical information, to quantify ILD extent, freestanding bronchial abnormalities, and lobar percentage involvement of PPFE on a 4-point categorical scale. Discordant scores were adjudicated by a third scorer. PPFE extent was further classified as limited ( $\leq 2/18$ ) or extensive ( $> 2/18$ ). Results were evaluated against functional decline and mortality.

The overall prevalence of PPFE in the combined SSc population was 18% (11% with extensive PPFE), with no substantial difference between the two cohorts. PPFE was significantly linked to free-standing bronchial abnormalities (61% vs 25% in PPFE vs no PPFE;  $p < 0.0001$ ) and to worse survival, independently of ILD severity or short-term lung function changes (HR 1.89, 95% CI 1.10-3.25;  $p = 0.005$ ).

In the current study, we provide an exhaustive description of PPFE prevalence and clinical impact in the largest cohort of SSc subjects published so far. PPFE presence should be carefully considered, due to its significant prognostic implications.

## **Introduction**

Systemic sclerosis (SSc, Scleroderma) is a rare, immune-mediated disorder, characterized by microvascular injury, circulating autoantibodies, and fibroblast activation, leading to fibrosis of the skin and visceral organs [1]. Lung involvement, including interstitial lung disease (ILD) and/or pulmonary hypertension, is the leading cause of morbidity and mortality [2]. ILD may range from subclinical to severe progressive lung fibrosis. Baseline functional impairment and short-term pulmonary function test (PFT) trends, along with ILD extent on high resolution computed tomography (HRCT), are currently the most informative prognostic tools in routine clinical practice [3,4]. Morphologically, nonspecific interstitial pneumonia (NSIP) is the most common pattern, while a usual interstitial pneumonia (UIP) pattern is seen in a minority. Little is known about prevalence and prognostic value of other parenchymal abnormalities [5]. In particular, no large-scale study has assessed presence and potential impact of pleuroparenchymal fibroelastosis (PPFE) in SSc.

PPFE is a specific clinical-pathological entity affecting the visceral pleura and the subpleural parenchyma with an upper-lobe predilection, characterized by elastin-rich intra-alveolar fibrosis and scattered fibroblastic foci [6]. Its pathogenesis is unclear, but the heterogeneous spectrum of clinical presentation and behavior suggests that it may represent the final expression of a variable interplay between immune dysregulation, environmental exposure and genetic predisposition [6]. PPFE can present as an idiopathic form, included in the latest ATS/ERS classification of idiopathic interstitial pneumonias [7], or in association with a variety of different conditions, including infection, lung and bone marrow transplantation and autoimmune diseases [8, 9]. Moreover, PPFE features are observed in association with other interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF) [10, 11], hypersensitivity pneumonitis (HP) [12] and familial forms of pulmonary fibrosis [13].

The aims of the present study were to estimate the prevalence of PPFE in large unselected consecutive cohorts of SSc patients, to assess its potential impact on survival and functional decline, and to evaluate the correlation between PPFE and selected radiological/clinical features.

## **Materials and methods**

Two cohorts were included: one from the Royal Brompton Hospital Interstitial Lung Diseases Unit, London, UK (RBH cohort), the other from the rheumatological center of the Clinica Medica of University Hospital “Ospedali Riuniti”, Ancona, Italy (Ancona cohort). Ethical approvals for this study of clinically indicated HRCT and pulmonary function data were obtained from the Institutional Ethics Committees of RBH and of “Ospedali Riuniti”, respectively.

### *Patients and clinical information*

Consecutive patients with a diagnosis of SSc according to recommended criteria [14], presenting to RBH between 1990 and 2011 and to Ancona between 2002 and 2014 were eligible for inclusion in the absence of the following exclusion criteria: 1) overlap with other connective tissue disease; 2) unavailability of the HRCT scan; 3) predominant radiological features suggestive of vasculopathy (Supplementary Material).

Demographic factors and selected disease-related characteristics were collected for all SSc cases. These included: age, sex, smoking history, disease duration (defined as months from the onset of the first non-Raynaud’s phenomenon clinical manifestation), cutaneous subset (limited/diffuse), serum autoantibodies, pulmonary hypertension (defined as a systolic pulmonary arterial pressure  $\geq 40$  mmHg by echocardiography and/or a mean pulmonary artery pressure  $\geq 25$  mmHg by right heart catheterization), previous and/or concomitant treatments (corticosteroids and/or immunosuppressant drugs). Treatment status was sub-categorized as either “intention to treat” (treatment instituted within 3

months of presentation or continuation of pre-existing treatment) or “intention to observe” (no therapy at 3 months of follow-up).

PFT measurements (expressed as absolute value and percent predicted) were recorded if performed within 6 months of chest HRCT. They included forced vital capacity (FVC), forced expiratory volume in 1s (FEV<sub>1</sub>), and diffusing capacity of the lungs for carbon monoxide (DLco). The composite physiological index (CPI) was calculated using the formula:  $91.0 - (0.65 \times \% \text{ predicted DLco}) - (0.53 \times \% \text{ predicted FVC}) + (0.34 \times \% \text{ predicted FEV}_1)$ .

The presence of either limited or extensive ILD involvement in SSc was defined according to the staging system proposed by Goh et al, based on integration of HRCT evaluation and FVC estimation (Supplementary materials) [3].

For the UK cohort, all sequential lung function tests, routinely collected and available from baseline until last visit or death were also analyzed. Trends were analyzed as continuous change and as categorical change in separate models. FVC and DLco changes were computed as the percent change relative to the absolute values at baseline. We did not record longitudinal lung function measurements in the Italian cohort, as most patients did not undergo routine PFTs on follow up.

#### *HRCT analysis*

HRCT scans were evaluated independently by two experienced radiologists, with a third scorer adjudicating discordant scores. Scorers assessed PPFE features and extent [13], total ILD extent as well as freestanding bronchial abnormalities [12, 15,16]. The extent of pleural surface involvement from PPFE in each lobe was evaluated on a 4-point categorical scale. PPFE extent was further classified as limited ( $\leq 2/18$ ) or extensive ( $> 2/18$ ). Further details of the scoring methodology are provided in the Supplementary materials.

### *Statistical analysis*

Analyses were performed using SAS (version 9.4). Group comparisons were made using Student's *t* test, Wilcoxon rank sum,  $\chi^2$  statistics and Fisher's exact test, as appropriate. Interobserver variation for visual score between radiologists was assessed using the weighted Kappa statistics.

Mortality and disease progression were quantified from the date of the first available HRCT up to March 2018. Univariable and multivariable Cox proportional hazard analysis was undertaken to investigate determinants of mortality. Multivariable models always included terms for age, sex, cohort, PPFE, Goh et al staging system or CPI, FVC, DLco, active treatment, pulmonary hypertension, body mass index (BMI) and smoking status. We considered the composite categorical decline (CCD) at two years, defined as either a decline in FVC of  $\geq 10\%$  or a decline in FVC of 5-9% in combination with a decline in DLco of  $\geq 15\%$ . This was included as time-dependent covariate in multivariable survival analysis.

The relationship between PPFE and the annual rate of decline in absolute FVC values (measured as millimeters per year) from the date of HRCT to the end of follow up, with all available FVC values included, was analyzed by using a random coefficient regression model (with random slopes and intercepts) that included sex and age as covariates.

## **Results**

Of the initial 705 patients screened, 261 were excluded as the chest HRCT was not available for assessment. However, no differences in ILD severity were seen between patients included in the study and those excluded because of unavailable HRCT (Supplementary Material). Of the remaining 444 patients, 45 were excluded because of overlap with other connective tissue diseases and 40 due to the presence of predominant vasculopathy features on HRCT. A total of 359 patients were included in the present study, of which 228 from RBH and 131 from Ancona (Figure 1).



Demographic and clinical characteristics of the combined cohort and by center are summarized in Table 1. The mean age was 53.6 ( $\pm 13.2$ ) years, and the majority of patients were females (76.8%) and nonsmokers (58%), without significant differences according to cohort. Disease duration was similar in the two cohorts ( $74.9 \pm 85.6$  and  $62.8 \pm 86.5$  months), the limited cutaneous subtype was more frequent than the diffuse in both cohorts, and no substantial difference was detected in anti-topoisomerase antibody frequency. Lung involvement was significantly worse in the UK cohort, as documented by worse lung function parameters, higher mean CPI, greater ILD extent on HRCT, more frequent extensive ILD stage [3], prevalence of pulmonary hypertension, and higher proportion of subjects on “intention to treat” (Table 1). Median follow up time was 6.7 years in UK cohort and 8.6 years in the Italian cohort. With reference to radiological features other than PPFE, the prevalence of emphysema was approximately 15%, with no substantial difference between subgroups. Freestanding bronchial abnormalities were overall present in up to one third of the study population (32%), with a higher proportion in the Italian cohort (respectively 38% and 28%).

#### *Prevalence of PPFE and associations with selected features*

PPFE was detected in 65 of 359 SSc patients (PPFE+ 18.1%), of whom 41 (11.4%) had extensive PPFE. The prevalence of PPFE, overall and by extent (limited/extensive) was similar in the two cohorts (Table 2). Interobserver agreement for the presence of PPFE was good (weighted kappa statistics: 0.67). A comparison of demographic, clinical and radiological characteristics according to the presence of PPFE is shown in Table 3. Age, sex, smoking status, cutaneous subtype, anti-topoisomerase antibody frequency, active treatment and presence of PH did not differ between PPFE+ and PPFE- subgroups. PPFE was associated with a trend towards longer disease duration, a slightly lower mean ILD extent at HRCT, and more severe functional impairment (in FVC and DLco predicted values), although these differences did not reach statistical significance.

Body mass index (BMI) was significantly lower in PPFE+ compared to PPFE- patients ( $21.2 \pm 3.53$  and  $25.3 \pm 4.91$ , respectively). The prevalence of freestanding bronchial abnormalities was markedly higher in patients with PPFE compared to those without (61% in PPFE+ group vs 25% in PPFE- group,  $p < 0.0001$ ). There was no statistical difference in the prevalence of emphysema according to PPFE presence (14% in patients with and without PPFE).

### *Prognostic impact of PPFE*

Data on survival were available for 344 patients (PPFE- subgroup=281; PPFE+ subgroup=63). As no difference was observed in the prevalence of PPFE or in its severity according to centre, the analysis of the relationship between PPFE and survival was performed using the combined cohorts, although cohorts were adjusted for in the multivariable analysis. The presence of PPFE on HRCT was significantly associated with increased mortality on univariable analysis (HR: 1.56, 95% CI 1.02-2.40;  $p=0.04$ ) (Figure 1 and Supplementary Table 2S). There were 28 deaths in PPFE+ subgroup (44%) and 92 in PPFE- subgroup (32%). Multivariable analyses are reported in Table 4, providing a base model, adjusted for age, sex, cohort, and Goh staging system, and a full model, including also active treatment, pulmonary hypertension, BMI and smoking status. The association, if anything, was stronger in both models (HR 1.79, 95% CI 1.16-2.78;  $p=0.009$  in base model; HR 1.89, 95% CI 1.10-3.25;  $p=0.02$  in full model) (Table 4). In order to assess whether the relationship with PPFE was influenced by short term lung function changes, the full model also included the CCD variable, with no change in the association between PPFE and survival (Table 4). When CPI was used in a separate multivariable model, the association between PPFE and survival remained significant (HR 1.60, 95% CI 1.03-2.50;  $p=0.04$ ).

With regard to the severity of PPFE, we observed a trend towards a worse survival both in patients with limited and with extensive PPFE, compared to PPFE- patients, although in view of the small numbers

in each subgroup (Table 2S), this did not reach statistical significance both on univariable and multivariable analyses.

In the UK cohort alone, we analyzed the relationship between PPFE and the adjusted annual rate of decline in absolute FVC values. A trend towards higher decline in absolute FVC values (66 ml/year vs 44 ml/year,  $p=0.08$ ) was detected, although only of borderline significance. This did not change after adjusting for disease extent or “intention to treat” (data not shown).

## **Discussion**

The present study provides a detailed assessment of PPFE prevalence, associations and clinical impact in a large cohort of SSc patients, derived from two referral centers in two different countries. PPFE was present in approximately 18% of patients, and was an independent predictor of worse prognosis.

Interestingly, the prevalence of PPFE was essentially the same in the two populations, despite a significant difference in ILD severity. The UK population was derived from a tertiary ILD referral center and thus characterized by more severe ILD compared to the Italian cohort, which was retrieved from a rheumatology referral center for SSc, less selected in terms of pulmonary involvement. This suggests that the genesis and progression of PPFE in SSc is not necessarily linked to the progression of the background ILD pattern and may have alternative explanations. Interestingly, we observed a strong association between PPFE and freestanding bronchial abnormalities, although this link remains to be explained.

These results are in line with a previous Japanese study evaluating prevalence and prognosis of radiological PPFE lesions in a cohort of patients with CTD-ILDs ( $n = 113$ ), including 14 subjects with SSc. The overall prevalence of PPFE in the whole CTD population was 19%, with the highest peak in the SSc subgroup (43%) and survival analysis in a multivariable model showed that PPFE presence

was a significant risk factor for mortality due to respiratory causes [9]. We also found that the presence of PPFE features is independently associated with an excess mortality risk by 77% on multivariable analysis that included age, Goh et al staging system (or CPI in separate models), BMI, progressive functional decline (CCD at 2 years), intention to treat and pulmonary hypertension. Potential determinants of a worse survival may include direct mechanisms, such as the marked functional restriction in these patients and/or more rapid lung function decline, as well as indirect/systemic effects, such as a reduced BMI and/or higher susceptibility to infections. A more rapid rate of lung function decline is a further pathological mechanism that might be linked to a higher mortality, as we observed a trend bordering on statistical significance towards a greater rate of decline in FVC in patients with PPFE. However, as longitudinal lung function was only available for the UK cohort, further studies are needed to assess the link between PPFE and lung function decline in different populations. We find a strong association with low BMI in PPFE+ subjects, with BMI predictive of worse survival on univariable analysis in our cohort. Although the association was no longer significant on multivariable analysis, a low BMI may well be contributing to the poor survival in this cohort. A low or decreasing BMI is known to be an independent predictor of increased mortality in patients with IPF [17-20].

With reference to the higher susceptibility to infections in these patients, it is worth underlining the strong association between PPFE and freestanding bronchiectasis, found in both our cohorts. The higher prevalence of freestanding bronchial abnormalities in subjects with PPFE (33.7% vs 1.1%,  $p < 0.0001$ ) is consistent with findings in a large IPF cohort (N=274) [10]. The strong link between PPFE and freestanding bronchiectasis supports the hypothesis that PPFE might represent an aberrant fibrosing immune response to repeated infections and inhaled antigens. In the paper by Reddy et al, over half of PPFE patients reported recurrent infections, including allergic bronchopulmonary aspergillosis, and aspergilloma [13], and Piciucchi et al. documented a PPFE case of a patient who

tested positive for *Aspergillus precipitins* [21]. Moreover, no significant association was found between PPFE and smoking history, confirming previous observations [12].

We did not observe increased mortality in extensive PPFE, compared to limited PPFE, despite the fact that the extensive PPFE has been linked to higher mortality in IPF and HP [10,12]. This is possibly due to the the low number of observations, or to a different interaction operating in SSc-ILD patients.

The study had limitations. Although the CT appearance of PPFE has been defined [13], tissue corroboration was lacking in our cohorts. However, as the histological distinction between a UIP and NSIP pattern does not change management in SSc-ILD [25,26], tissue biopsy is no longer performed in these patients. Thus, PPFE can be identified in SSc patients only by means of HRCT, and, therefore, our observations are applicable to routine clinical practice with PPFE identified with observed good inter-observer agreement. Selection bias must be acknowledged, as patients were evaluated at two national tertiary referral centers, and were, therefore, likely to have more severe pulmonary involvement than in unselected cohorts. Furthermore, there were differences in patient characteristics between the two centers. However, the presence of PPFE was not related to ILD severity, and, importantly, the linkage between PPFE and mortality was independent of ILD severity, the distinction between intention to treat and intention to observe, and the referral centre. Given these observations and the fact that the full spectrum of ILD severity was well-represented in the study cohort, we believe that our findings are likely to be generalizable.

A further potential bias is related to the exclusion of subjects with predominant features suggestive of vasculopathy at HRCT. In the absence of standardized radiological criteria, we adopted the features used to describe SSc-associated pulmonary veno-occlusive disease, including the presence of both centrilobular ground glass opacities and non-subpleural interlobular septal thickening [27, 28]. As indirect confirmation of the reliability of this definition in identifying vascular rather than interstitial changes, a reduction in DLCO with preserved lung volumes was observed in this excluded subgroup.

Lastly, due to the retrospective nature of this study, information on serological status was missing for many patients, and standardized data on the frequency of respiratory infections and other clinical features was not available.

In conclusion, the increasing awareness of PPFE among specialists over recent years has led to an increase in its identification in both idiopathic and secondary contexts, suggesting that it is not as rare as previously thought. In the current study, we describe PPFE prevalence, extent and clinical impact in the largest cohort of SSc subjects published so far. Our results indicate that its presence should be carefully considered, due to its significant prognostic implications. Owing to the absence of effective tailored treatments, the identification of PPFE does not currently alter management of this subgroup of SSc patients, but greater awareness, surveillance and careful prevention of infections is recommended. Further studies are needed to better define the pathogenesis and optimal management of PPFE.

## **Acknowledgments**

This work was supported in part by Versus Arthritis and by Scleroderma and Raynaud's UK.

Joseph Jacob was funded by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z.

We thank Professor David Hansell for his invaluable contribution to the design of this study.

## References

1. Desbois AC, Cacoub P. Systemic sclerosis: An update in 2016. *Autoimmun Rev* 2016; 15: 417-26.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. *Ann Rheum Dis* 2007; 66: 940-4.
3. Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med* 2008; 177: 1248-54.
4. Goh NS, Hoyles RK, Denton CP et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. *Arthritis Rheumatol* 2017; 69: 1670-8.
5. Denton CP, Khanna D. Systemic sclerosis. *Lancet* 2017.
6. Bonifazi M, Montero MA, Renzoni EA. Idiopathic Pleuroparenchymal Fibroelastosis. *Curr Pulmonol Rep* 2017; 6: 9-15.
7. Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013; 188: 733-48.
8. Mariani F, Gatti B, Rocca A et al. Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. *Diagn Interv Radiol* 2016; 22: 400-6.
9. Enomoto Y, Nakamura Y, Colby TV et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. *PLoS One* 2017; 12: e0180283.
10. De Lauretis A, Basra H, Hakim W. Pleuroparenchymal Fibroelastosis (PPFE) Predicts Survival in Idiopathic Pulmonary Fibrosis (IPF). A1142, 1110.1164/ajrccm-conference.2016.1193.1141\_MeetingAbstracts. 2016.
11. Oda T, Ogura T, Kitamura H et al. Distinct characteristics of pleuroparenchymal fibroelastosis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis. *Chest* 2014; 146: 1248-55.
12. Jacob J, Odink A, Brun AL et al. Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. *Respir Med* 2018; 138: 95-101.
13. Reddy TL, Tominaga M, Hansell DM et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. *Eur Respir J* 2012; 40: 377-85.

14. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis Rheum* 2013; 65: 2737-47.
15. Cowman SA, Jacob J, Hansell DM et al. Whole-Blood Gene Expression in Pulmonary Nontuberculous Mycobacterial Infection. *Am J Respir Cell Mol Biol* 2018; 58: 510-18.
16. de Jong PA, Ottink MD, Robben SG et al. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. *Radiology* 2004; 231: 434-9.
17. Kim JH, Lee JH, Ryu YJ et al. Clinical predictors of survival in idiopathic pulmonary fibrosis. *Tuberc Respir Dis (Seoul)*. 2012;73 :162-8
18. Kulkarni T, Yuan K, Tran-Nguyen TK et al. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. *PLoS One* 2019;14:e0221905
19. Kishaba T, Nagano H, Nei Y, Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. *J Thorac Dis*. 2016;8:3596-604
20. Jouneau S, Lederlin M, Vernhet L et al Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity! *Eur Respir J*. 2019;53. pii: 1900418.21.
21. Piciucchi S, Tomassetti S, Casoni G et al. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. *Respir Res* 2011; 12: 111.
22. Khiroya R, Macaluso C, Montero MA et al. Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival. *Am J Surg Pathol* 2017; 41: 1683-9.
23. Bargagli E, Rottoli P, Torricelli E et al. Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity. *Pathobiology* 2018; 85: 276-9.
24. Kronborg-White S, Ravaglia C, Dubini A et al. Cryobiopsies are diagnostic in Pleuroparenchymal and Airway-centered Fibroelastosis. *Respir Res* 2018; 19: 135.
25. Bouros D, Wells AU, Nicholson AG et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. *Am J Respir Crit Care Med*. 2002;165:1581-6.
26. Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management. *Nat Rev Rheumatol*. 2014;10:728-39



27. Duarte AC, Cordeiro A, Loureiro MJ, Ferreira F. Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis. *Clin Rheumatol* 2020. doi: 10.1007/s10067-020-04953-4
28. Connolly MJ, Abdullah S, Ridout DA et al. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. *Rheumatology (Oxford)* 2017; 56: 2197-203.

Characteristics	Whole cohort (n=359)	RBH cohort (n=228)	Ancona cohort (n=131)	P
Age, years	53.6 ± 13.2	53.2 ± 12.5	54.3 ± 14.4	0.4
Sex, no. male/no. female	83/276	58/170	25/106	0.1
Smoking status, no./ no. assessed (%) (n=325)				
<i>Never smokers</i>	189 (58)	124/217 (57)	65/108 (60)	0.3
<i>Ever- smokers</i>	136 (42)	93/217 (43)	43/108 (40)	
Duration of systemic disease, median months	70.5 ± 85.9	74.9 ± 85.6	62.8 ± 86.5	0.2
Limited cutaneous SSc/diffuse cutaneous SSc, no (n=241)	158/83	67/43	91/40	0.06
Antitopoisomerase antibody positive/ no. assessed (%)	158/312 (50)	88/185 (48)	70/131 (53)	0.3
Active treatment at baseline/ no. assessed (%) (n=317)	167/317 (53)	146/186 (78)	21/131 (16)	<.0001
Presence of PH, no. (%) (n=336) <sup>√</sup>	73/336 (21)	66/205 (32)	7/131(5)	<.0001
Pulmonary function test at baseline, % predicted (n=319)	(n=319)	(n=226)	(n=93)	
FEV1	75.6 ± 21.6	71.6 ± 20.5	86.5 ± 21.2	< .0001
FVC	78.9 ± 23.4	74.6 ± 22.1	89.6 ± 23.2	<.0001
DLco	50.8 ± 19.5	45.4 ± 17.3	64.1 ± 17.9	<.0001
Kco	72.4 ± 18.8	69.2 ± 18.7	80.2 ± 16.8	<.0001
Limited/extensive ILD disease* (n= 347)	156/191	85/143	71/48	<.0001
CPI (n=300)	42.7 ± 16.9	46.6 ± 15.4	31.9 ± 16.1	<.0001
ILD average extent on HRCT	29.2 ± 13.2	32.8 ± 30.2	22.8 ± 18.7	<.0001
Extent < 5 percentage (n, %)	70/359 (19)	23/228 (10)	47/131 (36)	
Radiological features				
Any emphysema no(%)	51 (14)	35 (15)	16 (12)	0.4
-Trivial	22 (6)	13 (6)	9 (7)	
-Moderate/severe	29 (8)	22 (9)	7 (5)	
Any freestanding bronchial abnormalities no. (%)	114 (32)	64 (28)	50 (38)	0.04
-Bronchial dilatation	79 (22)	43 (19)	36 (27)	
-Bronchial wall thickening	70 (19)	38 (17)	32 (24)	

Table 1. Demographic, clinical and radiological characteristics of the whole cohort and by center

Values are reported as mean ± SD as Number (%), as appropriate.

<sup>√</sup> 34 diagnosed by right heart catheterization (mean pulmonary artery pressure ≥25 mmHg), 39 by echocardiogram (estimated pulmonary artery systolic pressure ≥40 mmHg) by echocardiogram.

\* According to Goh et al staging system [3]

CPI: composite physiological index; DLco: Diffusion capacity of the lung for carbon monoxide; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; HRCT: high resolution computed tomography; Kco: transfer coefficient of

the lung for carbon monoxide **ILD**: interstitial lung disease; **PH**: arterial pulmonary hypertension (defined as  $PASP \geq 40$  mmHg on echocardiogram and/or  $\geq 25$  mmHg on right heart catheterization); **SSc**: scleroderma

<b>Characteristics</b>	<b>Whole cohort (n=359)</b>	<b>RBH cohort (n=228)</b>	<b>Ancona cohort (n=131)</b>	<b><i>P</i></b>
PPFE	65 (18.1)	42 (18.4)	23 (17.5)	0.8
Limited	24 (6.7)	16 (7.0)	8 (6.1)	
Extensive	41 (11.4)	26 (11.4)	15 (11.4)	

Table 2. PPFE prevalence and extent in the whole cohort and by center

PPFE: pleuroparenchymal fibroelastosis

Table 3. Demographic, clinical and radiological characteristics according to PPFE presence.

Characteristics	Patients with PPFE (n=65)	Patients without PPFE (n=294)	P
Age, years	54.3 ± 11.5	53.4 ± 13.5	0.6
Sex, no. male/no. female	10/55	73/221	0.1
Smoking status, no. (n=315)	(n=56)	(n=259)	0.6
<i>Never smokers</i>	33 (59)	146 (49)	
<i>Ever- smokers</i>	23 (41)	113 (43)	
Body mass index (n=328)	21.2 ± 3.52	25.3 ± 4.91	<.0001
Duration of systemic disease, mean months	87.3 ± 89.2	66.8 ± 89.2	0.08
Limited cutaneous SSc/ no. assessed (%) (n=241)	25/40 (62)	133/201 (66)	0.6
Antitopoisomerase antibody positive/ no. assessed (%) (n=316)	28/57 (50)	130/259 (50)	0.3
“Intention to treat”/ no. assessed (%) (n=317)	30/59 (50)	137/258 (53)	0.7
Presence of PH, no./ no. assessed (%) (n=336)	15/61 (25)	58/275 (21)	0.6
Pulmonary function test at baseline, % predicted (n=319)	(n=59)	(n=260)	0.1 0.1 0.8
FVC	74.5 ± 24.6	80.0 ± 23.1	
DLco	47.6 ± 17.3	51.5 ± 19.8	
Kco	72.9 ± 19.9	72.3 ± 18.6	
ILD average extent on HRCT	26.9 ± 21.3	29.7 ± 22.7	0.3
Radiological features			0.9 <.0001 <.0001 <.0001
Any emphysema no. (%)	9 (14)	42 (14)	
Any freestanding bronchial abnormalities no. (%)	40 (61)	74 (25)	
-Bronchial dilatation	31 (48)	48 (16)	
-Bronchial wall thickening	27 (42)	43 (14)	

Values are reported as mean ± SD as Number (%), as appropriate. DLco: Diffusion capacity of the lung for carbon monoxide; FVC: forced vital capacity; Kco: transfer coefficient of the lung for carbon monoxide; HRCT: high resolution computed tomography; ILD: interstitial lung disease; Kco: PH: arterial pulmonary hypertension (defined as PASP ≥ 40 mmHg on echocardiogram and/or ≥ 25 mmHg on right heart catheterization); PPFE: pleuroparenchymal fibroelastosis; SSc: scleroderma

Table 4. Mortality in SSc patients according to selected covariates, expressed as hazard ratios (HR)

Characteristic	N	Base Model <sup>a</sup>		Full Model <sup>b</sup>	
		HR	95% CI	HR	95% CI
PPFE (yes)	332	1.79	1.16-2.78	1.89	1.10-3.25
Age (yrs)	332	1.04	1.02-1.06	1.05	1.03-1.07
Sex (Female)	332	1.57	1.05-2.33	1.71	1.05-2.77
Cohort (Italian)	332	0.43	0.26-0.69	0.57	0.21-0.53
FVC % pred (per 1% increase)	306	0.97	0.96-0.98	1.00	0.98-1.01
DLco % pred (per 1% increase)	304	0.94	0.93-0.96	0.95	0.92-0.97
ILD extent at HRCT (per 1% increase)	344	1.02	1.01-1.03	1.01	0.99-1.03
Goh et al staging system (extensive)	332	2.15	1.42-3.26	2.38	1.29-4.40
CPI (per unit increase)	288	1.05	1.03-1.06	1.05	1.03-1.08
CCD at 2 years <sup>c</sup> (yes)	332	4.14	2.85-6.00	5.95	3.56-8.78
Active treatment (yes)	296	1.24	0.69-2.21	1.71	0.83-3.49
Pulmonary hypertension (yes)	309	2.78	1.85-4.24	3.07	1.93-4.89
Smoking status (ever)	284	1.09	0.72-1.63	0.99	0.62-1.61
BMI (per kg/m <sup>2</sup> )	306	0.95	0.90-0.99	0.96	0.92-1.01

with 95% confidence intervals (CI)

DLco: carbon monoxide diffusion capacity; FVC: forced vital capacity; HR:hazard ratio; HRCT: high resolution computed tomography; ILD: interstitial lung disease; PH: arterial pulmonary hypertension (defined as PASP $\geq$ 40 mmHg on echocardiogram and/or  $\geq$ 25 mmHg on right heart catheterization); PPFE: pleuroparenchymal fibroelastosis; SSc: scleroderma.

<sup>a</sup> HR adjusted for age, sex, cohort, and Goh staging (except for ILD extent at HRCT and CPI)

<sup>b</sup> HR adjusted for all the characteristics listed in the table, except for ILD extent at HRCT, FVC%, DLco%, and CPI (N=227). For ILD extent at HRCT and, in a separate model CPI, HR adjusted for all the characteristics listed in the table except for Goh staging, DLco% and FVC% (N=216).


<sup>c</sup> time-dependent covariate

## **Figure legend**


**Figure 1.** Flow-chart of case inclusion in study

**Figure 2 A-B.** Axial HRCT images showing limited (A) and extensive (B) features of pleuroparenchymal fibroelastosis (PPFE). Fig. 2A highlights limited pleural and parenchymal aggregations of fibrous tissue in the upper lobes, and interstitial abnormalities in the lower lobes. Fig 2B shows extensive subpleural, parenchymal and airway-centered PPFE features in the upper lobe as well in the lower lobes

**Figure 3.** Survival comparison between patients with and without PPFE in the whole cohort (n=344)








### Product-Limit Survival Estimates

With Number of Subjects at Risk



PPFE ——— PPFE neg ——— PPFE pos

PPFE neg	281	239	193	138	90	67	26
PPFE pos	63	52	37	28	18	10	3

## Supplementary materials

### **Computed tomography (CT) features suggestive of vasculopathy**

Apparent interstitial lung abnormalities on HRCT were interpreted as suggestive of vasculopathy, when the following findings were observed: ‘either diffuse centrilobular ground glass opacities or non-subpleural conspicuous interlobular septal thickening, in the absence of HRCT features of fibrotic lung disease (e.g. honeycombing, subpleural reticulation with traction bronchiectasis)’, adopting the description proposed for SSc-associated pulmonary veno-occlusive disease [1, 2]. As indirect support for the presence of a predominant vasculopathy in the 40 excluded patients, a “vascular” lung function profile was observed in this group [3], with an isolated marked reduction in DLco % (mean value  $49.52 \pm 23.99\%$ ) and preserved lung volumes (FVC%: mean value  $91.01 \pm 27.88\%$ ), as expected for patients with little or no ILD and predominant pulmonary vasculopathy.

### **CT Protocols**

The CT scans were obtained using a 64-slice multiple detector CT scanner (Somatom Sensation 64, Siemens, Erlangen, Germany, at Royal Brompton Hospital; GE light speed VCT 64, GE healthcare, US , at Ancona Hospital) or a 4-slice multiple detector CT scanner (Siemens Volume Zoom, Siemens, Erlangen, Germany).

All patients were scanned from lung apices to bases, supine, at full inspiration, with 1·0 mm section thicknesses using a peak voltage of 120kVp with tube current modulation (range 30-140 mA). Images were viewed at window settings optimized for the assessment of the lung parenchyma (width 1500 H.U.; level -500 H.U.).

### **Qualitative and quantitative assessment of total ILD extent, PPFE features and airways abnormalities**

i) Total interstitial lung disease extent scoring:

ILD extent on HRCT was scored using a continuous scale at five representative axial levels. The chosen anatomical levels included: (1) the origin of the great vessels from the aorta, (2) the main carina, (3) the pulmonary venous confluence, (4) a point halfway between level 3 and 5, (5) immediately above the dome of the right hemidiaphragm. At each level, the total extent of ILD was

estimated to the nearest 5%. The extent of PPFE was not included in the total ILD extent. The scores for the five sections were averaged to generate overall ILD extent.

#### ii) PPFE scoring

The presence of PPFE was identified on a lobar basis according to previously defined CT criteria [4]. PPFE extent was scored on a 4-point categorical scale as: 0 = absent, 1 = mild, affecting < 10% of the pleural surface, 2 = moderate, affecting 10–33% of the pleural surface, 3 = severe, affecting > 33% of the pleural surface. Lobar PPFE scores were summed for each patient to create an overall 18-point (potential scores of 0–18) scale for total PPFE. Severity of total PPFE scores was categorized as follows: limited =  $\leq 2$ ; extensive  $> 2$  (examples reported in Figure 2 A-B) [5].

#### iii) Airway scoring and emphysema

Freestanding bronchial abnormalities (in areas separate from the PPFE and from ILD changes), were evaluated on a three-point categorical scale, using the following scoring system: bronchial wall thickening: 0 = absent, 1 = mild, 2 = severe; bronchial dilatation: 0 = absent, 1 = dilatation not reaching CT criteria for bronchiectasis, 2 = dilatation reaching CT criteria for bronchiectasis [5-8]

Emphysema extent was assessed on a three-point categorical scale, as follows: 0 = absent, 1 = trivial (<10%), 2 = moderate/severe ( $\geq 10\%$ ) [9,10]. Pleural thickening was evaluated on a three-point categorical scale: 0 = absent, 1 = 25%, 2 =  $\geq 25\%$ .

The presence/absence of an obvious suprasternal depression was also recorded.

#### iii) Consensus formulation

Given that PPFE is a relatively new radiological sign, deriving a consensus for the PPFE scores of the two radiologists was achieved with a third experienced scorer (S.P.) with over 15 years of thoracic imaging experience. Any case in which only one of the original two scorers had identified PPFE features in the lungs (presence versus absence of PPFE) was arbitrated by the third scorer. Furthermore, any case with maximum lobar PPFE extent <10% (Grade 1/trivial PPFE) by both scorers was also consented by the third scorer to avoid over-estimation of PPFE. Once a consensus for all the lobar scores had been reached, the lobar scores were summed for each patient (PPFE extent).

#### **Goh et al staging system evaluation:**

HRCT disease extent thresholds of 10% and 30% is used to identify patients readily classifiable as having limited or extensive disease (HRCT  $\leq 10\%$ : limited; HRCT extent  $> 30\%$ : extensive). When HRCT disease extent lay between 11 and 30%, a threshold of FVC levels (< or  $\geq 70\%$  predicted) is used for classifying as limited or extensive disease. In other words, in presence of a HRCT disease

extent between 11 and 30%, the disease is defined as limited if FVC is  $\geq 70\%$  predicted, while as extensive if FVC is  $<70\%$  predicted [11].

#### **Comparison between cohort excluded due to the absence of HRCT and included cohort**

To explore potential selection bias, we compared lung function parameters between patients excluded due to the absence of HRCT (n=261) and those included (N= 359), and we did not find substantial differences. Mean FVC% predicted and mean DLco% predicted were respectively 82.06 ( $\pm 23.34$ ) % and 54.01 ( $\pm 19.09$ )% in the excluded cohort and not significantly different from those of included cohort (mean values FVC% 78% and Dlco 50%; p=0.3).

#### **Comparison of CPI values at baseline according to treatment status**

CPI of “intention to treat” subgroup:  $51.10 \pm 14.96$ ; CPI of “Intention to observe” subgroup:  $31.47 \pm 13.72$ ; p <0.00001

#### **FEV1 and Tiffenau values in subjects with freestanding bronchial abnormalities**

FEV1 % predicted mean value:  $79.94 \pm 21.81$

Tiffenau (FEV1/FVC) mean value:  $0.95 \pm 0.14$

<b>Type of treatment at baseline *</b>	<b>Whole cohort (n=317)</b>	<b>RBH cohort (n=186)</b>	<b>Ancona cohort (n=131)</b>
None	150 (48)	40 (21)	110 (85)
Oral corticosteroids only	43 (14)	37 (19)	6 (4)
Conventional Immunosuppressants only **	39 (12)	36 (20)	3 (2)
Biologics only ***	8 (2)	4 (2)	4 (3)
Oral corticosteroids + conventional immunosuppressants	77 (24)	69 (38)	8 (6)

**Table 1 S. Type of treatment of the whole cohort and by center**

\* Treatment at baseline was considered the treatment instituted within 3 months since or continuation of pre-existing treatment up to three months

\*\*Cyclophosphamide, methotrexate, mycophenolate, azathioprine, hydroxychloroquine, ciclosporin

\*\*\* Rituximab, Infliximab, Imatinib

**Table 2.S. Mortality, expressed as hazards ratio with 95% confidence intervals, in relation to baseline data (univariable analysis)**

Characteristics	Univariable analysis		
	HR	95% CI	<i>p</i>
<b>PPFE</b>	1.57	1.02-2.40	0.04
- <i>PPFE limited</i>	1.54	0.78-3.05	0.21
- <i>PPFE extensive</i>	1.42	0.89-2.31	0.16
<b>Age (yrs)</b>	1.03	1.02-1.05	<.0001
<b>Gender (female)</b>	1.97	1.32-2.93	0.0008
<b>Cohort (Italian)</b>	0.37	0.24-0.58	<.0001
<b>% predicted FVC</b>	0.97	0.96-0.98	<.0001
<b>% predicted DLco</b>	0.95	0.94-0.96	<.0001
<b>ILD extent</b>	1.02	1.01-1.03	<.0001
<b>CPI</b>	1.05	1.03-1.06	<.0001
<b>Goh et al staging system</b>	2.31	1.52-3.52	<.0001
<b>Smoking history</b>	1.06	0.71-1.56	0.76
<b>Active treatment</b>	2.62	1.72-4.00	<.0001

## References

1. Duarte AC, Cordeiro A, Loureiro MJ, Ferreira F. Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis. *Clin Rheumatol* 2020.
2. Connolly MJ, Abdullah S, Ridout DA et al. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. *Rheumatology (Oxford)* 2017; 56: 2197-203.
3. Denton CP, Wells AU, Coghlan JG Major lung complications of systemic sclerosis. *Nat Rev Rheumatol*. 2018;14:511-527.
4. Reddy TL, Tominaga M, Hansell DM et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. *Eur Respir J* 2012; 40: 377-85.
5. Jacob J, Odink A, Brun AL et al. Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. *Respir Med* 2018; 138: 95-101.
6. Cowman SA, Jacob J, Hansell DM et al. Whole-Blood Gene Expression in Pulmonary Nontuberculous Mycobacterial Infection. *Am J Respir Cell Mol Biol* 2018; 58: 510-8.
7. de Jong PA, Ottink MD, Robben SG et al. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. *Radiology* 2004; 231: 434-9.
8. Alton E, Armstrong DK, Ashby D et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Respir Med* 2015; 3: 684-91.
9. Ryerson CJ, Hartman T, Elicker BM et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. *Chest* 2013; 144: 234-40.
10. Pescarolo M, Sverzellati N, Verduri A et al. How much do GOLD stages reflect CT abnormalities in COPD patients? *Radiol Med* 2008; 113: 817-29.
11. Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med* 2008; 177: 1248-54